MAB8257B
Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated
clone A1, Chemicon®, from mouse
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Productos recomendados
biological source
mouse
Quality Level
conjugate
biotin conjugate
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
A1, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable
isotype
IgG2a
shipped in
wet ice
Specificity
Specific for the Influenza A nucleoprotein. Has stronger binding with N1-type Flu A. Has been shown to react with the H5N1 strain. No cross reactivity seen to influenza B or other respiratory viruses.
Immunogen
Epitope: nucleoprotein
Influenza A
Application
Detect Influenza A using this Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated validated for use in IF.
Immunofluorescence
Optimal dilutions must be determined by end user.
Optimal dilutions must be determined by end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Physical form
Biotin conjugated purified immunoglobulin. Liquid in 0.01M PBS, pH=7.1, 0.1% Sodium Azide with 15 mg/mL BSA as stabilizer.
Storage and Stability
Maintain at 2 to 8°C for up to 12 months from date of receipt. Protect from Light.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Storage Class
12 - Non Combustible Liquids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Mehfuz Zaman et al.
Clinical & translational immunology, 10(9), e1337-e1337 (2021-09-17)
The upper respiratory tract is the major entry site for Streptococcus pyogenes and influenza virus. Vaccine strategies that activate mucosal immunity could significantly reduce morbidity and mortality because of these pathogens. The severity of influenza is significantly greater if a
Kai Wu et al.
ACS applied materials & interfaces, 14(8), 9945-9969 (2022-02-16)
The giant magnetoresistance (GMR) effect has seen flourishing development from theory to application in the last three decades since its discovery in 1988. Nowadays, commercial devices based on the GMR effect, such as hard-disk drives, biosensors, magnetic field sensors, microelectromechanical
Roozbeh Abedini-Nassab et al.
Micromachines, 12(7) (2021-07-03)
Magnetic nanoparticles have attracted significant attention in various disciplines, including engineering and medicine. Microfluidic chips and lab-on-a-chip devices, with precise control over small volumes of fluids and tiny particles, are appropriate tools for the synthesis, manipulation, and evaluation of nanoparticles.
Felix Broecker et al.
NPJ vaccines, 4, 31-31 (2019-07-26)
Current seasonal influenza virus vaccines only provide limited, short-lived protection, and antigenic drift in the hemagglutinin surface glycoprotein necessitates their annual re-formulation and re-administration. To overcome these limitations, universal vaccine strategies that aim at eliciting broadly protective antibodies to conserved
Sergey Yegorov et al.
Cell reports. Medicine, 3(2), 100509-100509 (2022-03-05)
The induction of broadly neutralizing antibodies (bNAbs) that target the hemagglutinin stalk domain is a promising strategy for the development of "universal" influenza virus vaccines. bNAbs can be boosted in adults by sequential exposure to heterosubtypic viruses through natural infection
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico